このエントリーをはてなブックマークに追加


ID 62782
JaLCDOI
フルテキストURL
75_5_663.pdf 1.99 MB
著者
Sadahira, Takuya Department of Urology, Okayama University Hospital
Maruyama, Yuki Department of Urology, Okayama University Hospital
Hiyama, Yoshiki Hakodate Goryoukaku Hospital
Kitano, Hiroyuki Hiroshima University Hospital
Yamada, Hiroki Jikei University Katsushika Medical Center
Goto, Takayuki Kyoto University Hospital
Kondo, Tsubasa Nagasaki University Hospital
Shigemura, Katsumi Kobe University Hospital
Mitsui, Yosuke Department of Urology, Okayama University Hospital
Iwata, Takehiro Department of Urology, Okayama University Hospital
Edamura, Kohei Department of Urology, Okayama University Hospital
Araki, Motoo Department of Urology, Okayama University Hospital
Watanabe, Masami Department of Urology, Okayama University Hospital
Takenaka, Tadasu Japanese Red Cross Okayama Hospital
Teishima, Jun Hiroshima University Hospital
Miyata, Yasuyoshi Nagasaki University Hospital
Ishikawa, Kiyohito Fujita Health University Hospital
Takaoka, Ei-Ichiro Internationla University of Health and Welfare Hospital
Miyazaki, Jun Internationla University of Health and Welfare Hospital
Takahashi, Satoshi Sapporo Medical University Hospital
Masumori, Naoya Sapporo Medical University Hospital
Kiyota, Hiroshi Jikei University Katsushika Medical Center
Fujisawa, Masato Kobe University Hospital
Yamamoto, Shingo Hyogo College of Medicine College Hospital
Sakuma, Takafumi Okayama Medical Center
Kusumi, Norihiro Okayama Medical Center
Ichikawa, Takaharu Okayama Medical Center
Watanabe, Toyohiko Department of Urology, Okayama University Hospital
Nasu, Yoshitsugu Okayama Rosai Hospital
Tsugawa, Masaya Okayama City General Medical Center
Nasu, Yasutomo Department of Urology, Okayama University Hospital
Wada, Koichiro Department of Urology, Okayama University Hospital
抄録
The aim of this report is to introduce an on-going, multicenter, randomized controlled trial to evaluate whether tailored antimicrobial prophylaxis guided by rectal culture screening prevents acute bacterial prostatitis following transrectal prostate biopsy (TRPB). Patients will be randomized into an intervention or non-intervention group; tazobactam-piperacillin or levofloxacin will be prophylactically administered according to the results of rectal culture prior to TRPB in the intervention group whereas levofloxacin will be routinely given in the non-intervention group. The primary endpoint is the occurrence rate of acute bacterial prostatitis after TRPB. Recruitment begins in April, 2021 and the target total sample size is 5,100 participants.
キーワード
antibiotic prophylaxis
selective culture media
prostate biopsy
fluoroquinolone-resistant
extended- spectrum beta-lactamase
Amo Type
Clinical Study Protocol
出版物タイトル
Acta Medica Okayama
発行日
2021-10
75巻
5号
出版者
Okayama University Medical School
開始ページ
663
終了ページ
667
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
英語
著作権者
CopyrightⒸ 2021 by Okayama University Medical School
論文のバージョン
publisher
査読
有り
PubMed ID
Web of Science KeyUT
NAID